Valuation China Resources Double-Crane Pharmaceutical Co.,Ltd.
Stocks
600062
CNE000000Q94
Pharmaceuticals
|
End-of-day quote
Shanghai S.E.
2026-10-26
|
5-day change | 1st Jan Change | ||
| 16.45 CNY | +2.81% |
|
+0.49% | -10.06% |
| 10-21 | CR Double-Crane Pharmaceutical Gets Registration Certificate for Baricitinib Tablets | MT |
| 10-20 | Double-Crane Pharmaceutical Subsidiary Gets China Approval for Hydrogen Phosphate Injection | MT |
Company Valuation: China Resources Double-Crane Pharmaceutical Co.,Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 13,948 | 18,276 | 18,992 | 20,323 | 18,885 | 16,990 | - | - |
| Change | - | 31.03% | 3.92% | 7.01% | -7.08% | -10.04% | - | - |
| Enterprise Value (EV) | 13,948 | 18,276 | 18,992 | 20,323 | 18,885 | 16,990 | 16,990 | 16,990 |
| Change | - | 31.03% | 3.92% | 7.01% | -7.08% | -10.04% | 0% | 0% |
| P/E | 14.9x | 15.9x | 14.3x | 12.5x | 11.5x | 9.62x | 8.99x | 8.06x |
| PBR | 1.41x | 1.86x | 1.74x | 1.98x | 1.63x | 1.32x | 1.2x | 1.07x |
| PEG | - | 0.6x | 0.9x | 0.6x | 20.24x | 1.31x | 1.28x | 0.7x |
| Capitalization / Revenue | 1.53x | 1.93x | 1.86x | 1.81x | 1.72x | 1.49x | 1.42x | 1.38x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 1.49x | 1.42x | 1.38x |
| EV / EBITDA | 0x | 0x | 0x | 0x | 0x | 6.14x | 5.77x | 5.59x |
| EV / EBIT | 0x | 0x | 0x | 0x | 0x | 8.36x | 7.81x | 7.11x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | 0.257 | 0.371 | 0.379 | 0.51 | 0.53 | - |
| Rate of return | - | - | 1.38% | 1.87% | 2.07% | 3.1% | 3.22% | - |
| EPS 2 | 0.8969 | 1.124 | 1.3 | 1.584 | 1.593 | 1.71 | 1.83 | 2.04 |
| Distribution rate | - | - | 19.8% | 23.4% | 23.8% | 29.8% | 29% | - |
| Net sales 1 | 9,112 | 9,447 | 10,222 | 11,212 | 11,001 | 11,393 | 11,976 | 12,351 |
| EBITDA 1 | 1,585 | 1,928 | 2,142 | 2,564 | 2,622 | 2,766 | 2,942 | 3,038 |
| EBIT 1 | 1,137 | 1,406 | 1,515 | 1,834 | 1,855 | 2,032 | 2,174 | 2,389 |
| Net income 1 | 935.7 | 1,164 | 1,333 | 1,628 | 1,647 | 1,776 | 1,900 | 2,114 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 13.37 | 17.89 | 18.60 | 19.80 | 18.29 | 16.45 | 16.45 | 16.45 |
| Nbr of stocks (in thousands) | 1,043,238 | 1,021,567 | 1,021,061 | 1,026,429 | 1,032,552 | 1,032,803 | - | - |
| Announcement Date | 3/24/22 | 3/27/23 | 3/21/24 | 3/19/25 | 3/19/26 | - | - | - |
1CNY in Million2CNY
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 9.36x | - | - | 3.19% | 2.48B | |
| 37.06x | 13.1x | 27.8x | 0.54% | 1,135B | |
| 38.61x | 6.49x | 18.27x | 2.02% | 635B | |
| 36.46x | 8.38x | 17.33x | 2.41% | 505B | |
| 20.87x | 5.11x | 12.73x | 2.56% | 378B | |
| 105.89x | 5.92x | 25.41x | 2.34% | 358B | |
| 21.76x | 5.68x | 13.94x | 2.81% | 295B | |
| 22.43x | 4.53x | 12.94x | 1.95% | 266B | |
| 27.87x | 7.16x | 12.81x | 2.3% | 237B | |
| -45.48x | 6.98x | 27.06x | 2.11% | 193B | |
| Average | 27.48x | 7.04x | 18.70x | 2.22% | 400.61B | |
| Weighted average by Cap. | 35.21x | 8.29x | 20.40x | 1.8% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 600062 Stock
- Valuation China Resources Double-Crane Pharmaceutical Co.,Ltd.
Select your edition
All financial news and data tailored to specific country editions
